Zobrazeno 1 - 10
of 47
pro vyhledávání: '"Talal El Zarif"'
Autor:
Talal El Zarif, Karl Semaan, Marc Eid, Ji-Heui Seo, Simon Garinet, Matthew P. Davidsohn, Pranshu Sahgal, Brad Fortunato, John Canniff, Amin H. Nassar, Sarah Abou Alaiwi, Ziad Bakouny, Gitanjali Lakshminarayanan, Hunter Savignano, Kevin Lyons, Sayed Matar, Atef Ali, Eddy Saad, Renee Maria Saliby, Paulo Cordeiro, Ziwei Zhang, Nourhan El Ahmar, Yasmin Nabil Laimon, Chris Labaki, Valisha Shah, Dory Freeman, Jillian O’Toole, Gwo-Shu Mary Lee, Justin Hwang, Mark Pomerantz, Sabina Signoretti, Eliezer M. Van Allen, Wanling Xie, Jacob E. Berchuck, Srinivas R. Viswanathan, David A. Braun, Toni K. Choueiri, Matthew L. Freedman, Sylvan C. Baca
Publikováno v:
Cell Reports, Vol 43, Iss 6, Pp 114350- (2024)
Summary: Renal cell carcinoma with sarcomatoid differentiation (sRCC) is associated with poor survival and a heightened response to immune checkpoint inhibitors (ICIs). Two major barriers to improving outcomes for sRCC are the limited understanding o
Externí odkaz:
https://doaj.org/article/a9e18e74ab10487c9c8418746dfe9c2a
Autor:
Lucia Kwak, So Yeon Kim, Guru Sonpavde, Elad Sharon, Abdul Rafeh Naqash, Alessio Cortellini, Rana R McKay, Toni K Choueiri, Thomas Marron, Amin H Nassar, Jeffrey A Sparks, Kaushal Parikh, Frank Aboubakar Nana, Jenny Linnoila, Shruti Gupta, Nicole R LeBoeuf, Elio Adib, Ahmad Al-Hader, Edward El-Am, Dory Freeman, Ahmed Bilal Khalid, Marita Salame, Elias Bou Farhat, Arjun Ravishankar, Bachar Ahmad, David Kaldas, Andrea Malgeri, Ole-Petter R Hamnvik, Thomas Dilling, Elie Najem, Talal El Zarif, Serena Rahme, Caiwei Zhong, Tarek H Mouhieddine
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 12, Iss 3 (2024)
Background Patients with paraneoplastic syndromes (PNS) are excluded from clinical trials involving immune checkpoint inhibitors (ICIs) due to safety concerns. Moreover, real-world data on efficacy and safety is scarce.Methods In this retrospective s
Externí odkaz:
https://doaj.org/article/e3a36a44dc60429b90c5ae6bfb360660
Autor:
Lucia Kwak, So Yeon Kim, Elad Sharon, Abdul Rafeh Naqash, Alessio Cortellini, Toni K Choueiri, Rana Mckay, Jeffrey A Sparks, Kaushal Parikh, Frank Aboubakar Nana, Jenny Linnoila, Shruti Gupta, Nicole R LeBoeuf, Elio Adib, Amin Nassar, Talal El Zarif, Ahmed Bilal Khalid, Serena J Rahme, Marita Salame, Elias Bou Farhat, Edward El Am, Arjun Ravishankar, Bachar Ahmad, David Kaldas, Andrea Malgeri, Ole-Petter R Hamnvik, Thomas Dilling, Elie Najem, Guru P Sonpavde
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/df99a0c739d64783afe5458e630339d9
Autor:
Amin H. Nassar, Sarah Abou Alaiwi, Sylvan C. Baca, Elio Adib, Rosario I. Corona, Ji-Heui Seo, Marcos A. S. Fonseca, Sandor Spisak, Talal El Zarif, Viktoria Tisza, David A. Braun, Heng Du, Monica He, Abdallah Flaifel, Michel Alchoueiry, Thomas Denize, Sayed G. Matar, Andres Acosta, Sachet Shukla, Yue Hou, John Steinharter, Gabrielle Bouchard, Jacob E. Berchuck, Edward O’Connor, Connor Bell, Pier Vitale Nuzzo, Gwo-Shu Mary Lee, Sabina Signoretti, Michelle S. Hirsch, Mark Pomerantz, Elizabeth Henske, Alexander Gusev, Kate Lawrenson, Toni K. Choueiri, David J. Kwiatkowski, Matthew L. Freedman
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-16 (2023)
The epigenomic landscape of renal cell carcinoma (RCC) remains to be explored. Here, integrative epigenomic analysis of primary human RCC samples and RCC GWAS risk SNPs identifies transcription-factor specific subtypes and enrichment of risk variants
Externí odkaz:
https://doaj.org/article/5c45bbe4ef1e4b0b9d9d760011ce2040
Autor:
Pier Vitale Nuzzo, Francesco Ravera, Calogero Saieva, Elisa Zanardi, Giuseppe Fotia, Andrea Malgeri, Sabrina Rossetti, Loana Bueno Valença, Talal El Zarif, Matthew P. Davidsohn, Heather McClure, Thiago Martins Oliveira, Charles Vauchier, Ricardo Pereira Mestre, Mikol Modesti, Praful Ravi, Anna Patrikidou, Sandro Pignata, Giuseppe Procopio, Giuseppe Fornarini, Ugo De Giorgi, Antonio Russo, Edoardo Francini
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 15 (2023)
Background: Androgen receptor signaling inhibitors (ARSis) abiraterone acetate (AA) plus prednisone and enzalutamide (Enza), are currently the most administered first-line treatments for metastatic castration-resistant prostate cancer (mCRPC). AA and
Externí odkaz:
https://doaj.org/article/fd32672558144154be2b5ca22e877ed5
Autor:
Xintao Qiu, Lisha G. Brown, Jennifer L. Conner, Holly M. Nguyen, Nadia Boufaied, Sarah Abou Alaiwi, Ji-Heui Seo, Talal El Zarif, Connor Bell, Edward O’Connor, Brian Hanratty, Mark Pomerantz, Matthew L. Freedman, Myles Brown, Michael C. Haffner, Peter S. Nelson, Felix Y. Feng, David P. Labbé, Henry W. Long, Eva Corey
Publikováno v:
JCI Insight, Vol 7, Iss 10 (2022)
The androgen receptor (AR) is a master transcription factor that regulates prostate cancer (PC) development and progression. Inhibition of AR signaling by androgen deprivation is the first-line therapy with initial efficacy for advanced and recurrent
Externí odkaz:
https://doaj.org/article/31afe18a58f34ea88bc2519a68bd658c
Autor:
Talal El Zarif, Mohamed Faisal Kassir, Nazih Bizri, Ghida Kassir, Umayya Musharrafieh, Abdul Rahman Bizri
Publikováno v:
BMC Infectious Diseases, Vol 20, Iss 1, Pp 1-10 (2020)
Abstract Background Lebanon has experienced several measles and mumps outbreaks in the past 20 years. In this article, a case-based surveillance of both measles and mumps outbreaks in Lebanon was carried out in an attempt to outline factors contribut
Externí odkaz:
https://doaj.org/article/1c89430a91604721b55a394e6460a052
Autor:
Talal El Zarif, Marcel Yibirin, Diana De Oliveira-Gomes, Marc Machaalani, Rashad Nawfal, Gianfranco Bittar, Hisham F. Bahmad, Nizar Bitar
Publikováno v:
Cancers, Vol 14, Iss 9, p 2105 (2022)
Colorectal cancer (CRC) is the third most common cancer in the world. Despite improvement in standardized screening methods and the development of promising therapies, the 5-year survival rates are as low as 10% in the metastatic setting. The increas
Externí odkaz:
https://doaj.org/article/424d9309320b455fb128dae44b6adbb6
Autor:
Ziad Bakouny, Talal El Zarif, Shaan Dudani, J. Connor Wells, Chun Loo Gan, Frede Donskov, Julia Shapiro, Ian D. Davis, Francis Parnis, Praful Ravi, John A. Steinharter, Neeraj Agarwal, Ajjai Alva, Lori Wood, Anil Kapoor, Jose M. Ruiz Morales, Christian Kollmannsberger, Benoit Beuselinck, Wanling Xie, Daniel Y.C. Heng, Toni K. Choueiri
Publikováno v:
European Urology. 83:145-151
The role of upfront cytoreductive nephrectomy (CN) for metastatic renal cell carcinoma (mRCC) in the era of immune checkpoint inhibitors is unclear.To evaluate the relationship between upfront CN and clinical outcomes in the setting of mRCC treated w
Autor:
Talal El Zarif, Amin H. Nassar, Elio Adib, Bailey G. Fitzgerald, Jiaming Huang, Tarek H. Mouhieddine, Paul G. Rubinstein, Taylor Nonato, Rana R. McKay, Mingjia Li, Arjun Mittra, Dwight H. Owen, Robert A. Baiocchi, Michael Lorentsen, Christopher Dittus, Nazli Dizman, Adewunmi Falohun, Noha Abdel-Wahab, Adi Diab, Anand Bankapur, Alexandra Reed, Chul Kim, Aakriti Arora, Neil J. Shah, Edward El-Am, Elie Kozaily, Wassim Abdallah, Ahmad Al-Hader, Batool Abu Ghazal, Anwaar Saeed, Claire Drolen, Melissa G. Lechner, Alexandra Drakaki, Javier Baena, Caroline A. Nebhan, Tarek Haykal, Michael A. Morse, Alessio Cortellini, David J. Pinato, Alessia Dalla Pria, Evan Hall, Veli Bakalov, Nathan Bahary, Aarthi Rajkumar, Ankit Mangla, Vishal Shah, Parminder Singh, Frank Aboubakar Nana, Nerea Lopetegui-Lia, Danai Dima, Ryan W. Dobbs, Pauline Funchain, Rabia Saleem, Rachel Woodford, Georgina V. Long, Alexander M. Menzies, Carlo Genova, Giulia Barletta, Sonam Puri, Vaia Florou, Dame Idossa, Maristella Saponara, Paola Queirolo, Giuseppe Lamberti, Alfredo Addeo, Melissa Bersanelli, Dory Freeman, Wanling Xie, Erin G. Reid, Elizabeth Y. Chiao, Elad Sharon, Douglas B. Johnson, Ramya Ramaswami, Mark Bower, Brinda Emu, Thomas U. Marron, Toni K. Choueiri, Lindsey R. Baden, Kathryn Lurain, Guru P. Sonpavde, Abdul Rafeh Naqash
Publikováno v:
Journal of Clinical Oncology.
PURPOSE Compared with people living without HIV (PWOH), people living with HIV (PWH) and cancer have traditionally been excluded from immune checkpoint inhibitor (ICI) trials. Furthermore, there is a paucity of real-world data on the use of ICIs in P